Immunogenicity of xenopeptide hormone therapiesSCHNABEL, Catherine A; FINEBERG, S. Edwin; KIM, Dennis D et al.Peptides (New York, NY. 1980). 2006, Vol 27, Num 7, pp 1902-1910, issn 0196-9781, 9 p.Article

Principles of vaccine design: Lessons from natureZEPP, Fred.Vaccine. Supplement. 2010, Vol 28, Num 3, issn 1359-5938, C14-C24Article

Relationships among physico-chemical and biological tests for a synthetic Hib-TT conjugate vaccineLANDYS CHOVEL CUERVO, Mario; PEREZ, Lidia Rosa; OVIEDO, Maite et al.Vaccine. 2007, Vol 25, Num 1, pp 194-200, issn 0264-410X, 7 p.Article

Biosimilars in rheumatology: pharmacological and pharmacoeconomic issuesLAPADULA, G; FERRACCIOLI, G. F.Clinical and experimental rheumatology (Testo stampato). 2012, Vol 30, Num 4, issn 0392-856X, S102-S106, SUP73Article

A new approach to the definition of seroconversion following vaccination in a population with high background antibody concentrationsCHANDRAMOHAN, Daniel; COLEMAN, Paul; NELSON, Chris et al.Vaccine. Supplement. 2007, Vol 25, Num 1, issn 1359-5938, A58-A62Article

An immunogenic cathepsin F secreted by the parasitic stages of Teladorsagia circumcinctaREDMOND, D. L; SMITH, S. K; HALLIDAY, A et al.International journal for parasitology. 2006, Vol 36, Num 3, pp 277-286, issn 0020-7519, 10 p.Article

A phase III randomized, controlled study to assess and compare the immunogenicity and tolerability of single and multi-dose vials of DTwP-Hib, a fully liquid quadravalent vaccine and their comparison with TETRAct-Hib vaccine in Indian infants aged 6-14 weeksSHARMA, Hitt; YADAV, Sangita; ASHTAGI, Girija et al.Vaccine. 2011, Vol 29, Num 48, pp 8773-8779, issn 0264-410X, 7 p.Article

Immunogenicity of therapeutic proteins. Part 2: Impact of container closuresSHARMA, Basant.Biotechnology advances. 2007, Vol 25, Num 3, pp 318-324, issn 0734-9750, 7 p.Article

Preventive vaccines against bioterrorism: evaluation of efficacy and safetyDALE HORNE, Amelia; CLIFFORD, Julianne; GOLDENTHAL, Karen L et al.Vaccine. 2004, Vol 23, Num 1, pp 84-90, issn 0264-410X, 7 p.Article

A palmitoyl-tailed sequential oligopeptide carrier for engineering immunogenic conjugatesKARGAKIS, Michael; ZEVGITI, Stella; KRIKORIAN, Dimitrios et al.Vaccine. 2007, Vol 25, Num 37-38, pp 6708-6712, issn 0264-410X, 5 p.Article

A Survey of Applications of Biological Products for Drug Interference of Immunogenicity AssaysWANG, Yow-Ming C; LANYAN FANG; LIN ZHOU et al.Pharmaceutical research. 2012, Vol 29, Num 12, pp 3384-3392, issn 0724-8741, 9 p.Article

Strategies for the preclinical and clinical characterization of immunogenicityKOREN, E; MYTYCH, D; KOSCEC, M et al.Developments in biologicals. 2005, Vol 122, pp 195-200, issn 1424-6074, 6 p.Conference Paper

AlphalLISA® Assays to Improve the Vaccine Development ProcessCOSENTINO, G.Developments in biologicals. 2012, Vol 134, pp 107-111, issn 1424-6074, 5 p.Conference Paper

An improved method for development of toxoid vaccines and antitoxinsJONES, Russell G. A; LIU, Yvonne; RIGSBY, Peter et al.Journal of immunological methods. 2008, Vol 337, Num 1, pp 42-48, issn 0022-1759, 7 p.Article

Interchangeability, immunogenicity and biosimilarsEBBERS, Hans C; CROW, Stacy A; VULTO, Arnold G et al.Nature biotechnology (Print). 2012, Vol 30, Num 12, pp 1186-1190, issn 1087-0156, 5 p.Article

A randomized study of a flexible booster dosing regimen of VAQTA® in adults: safety, tolerability, and immunogenicityHORNICK, Richard; TUCKER, Richard; KAPLAN, Karen M et al.Vaccine. 2001, Vol 19, Num 32, pp 4727-4731, issn 0264-410XArticle

Statistical considerations for calculation of immunogenicity screening assay cut pointsHOFFMAN, David; BERGER, Marion.Journal of immunological methods. 2011, Vol 373, Num 1-2, pp 200-208, issn 0022-1759, 9 p.Article

Identification and inhibition of drug target interference in immunogenicity assaysZHONG, Zhandong D; DINNOGEN, Steve; HOKOM, Martha et al.Journal of immunological methods. 2010, Vol 355, Num 1-2, pp 21-28, issn 0022-1759, 8 p.Article

A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distributionSCHLAIN, Brian; AMARAVADI, Lakshmi; DONLEY, Jean et al.Journal of immunological methods. 2010, Vol 352, Num 1-2, pp 161-168, issn 0022-1759, 8 p.Article

PEGylation of alpha-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potentialXIAOXIAO BIAN; FUBING SHEN; YIWEN CHEN et al.Biotechnology letters. 2010, Vol 32, Num 7, pp 883-890, issn 0141-5492, 8 p.Article

Influenza vaccinesELLEBEDY, A. H; WEBBY, R. J.Vaccine. Supplement. 2009, Vol 27, Num 4, issn 1359-5938, D65-D68Article

Statistical considerations for vaccine immunogenicity trials. Part 2: Noninferiority and other statistical approaches to vaccine evaluationPLIKAYTIS, Brian D; CARLONE, George M.Vaccine. 2005, Vol 23, Num 13, pp 1606-1614, issn 0264-410X, 9 p.Article

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsMIRE-SLUIS, Anthony R; BARRETT, Yu Chen; SWANSON, Steven J et al.Journal of immunological methods. 2004, Vol 289, Num 1-2, pp 1-16, issn 0022-1759, 16 p.Article

Development of a quadrivalent combined DTaP-HepB vaccine with a low toxicity and a stable HBsAg immunogenicityBAE, Cheon-Soon; PARK, Kyung-Nam; AHN, Sang-Jeom et al.Journal of microbiology and biotechnology. 2002, Vol 12, Num 5, pp 787-792, issn 1017-7825, 6 p.Article

Comparison of recombinant and native pertactin of Bordetella pertussisYINGHUA XU; SHUMIN ZHANG; BOLGIANO, Barbara et al.Vaccine. 2011, Vol 29, Num 10, pp 1974-1980, issn 0264-410X, 7 p.Article